Checked: 23-08-2021 by
Vicky Ryan Next Review: 23-08-2022
Overview
These guidelines have been provided by the Endocrinology Team at NBT so pathways might be slightly different at UHBW
Definition
An elevated serum prolactin which may be physiologically, pathologically or pharmacologically induced
Important points
May be asymptomatic but untreated, can result in galactorrhoea, infertility, hypogonadism and accelerated bone loss
A single measurement ≥ 700 mu/L usually confirms the diagnosis, as long as the serum sample was obtained with minimal venepuncture stress.
Who to refer
Patients with hyperprolactinaemia should be referred routinely to endocrinology via eRS.
Medication induced hyperprolactinaemia
For likely medication induced symptomatic hyperprolactinaemia, stop the medication for 3 days OR switch to a mediation with lower dopamine antagonist potency e.g. aripiprazole (discuss with the patient’s team e.g. Psychiatry)
- Re-measure the prolactin after 3 days
- If the drug cannot be stopped, the raised prolactin doesn’t coincide with starting the medication OR the prolactin remains raised despite 3 days off medication, investigate and refer.
See the Psychotropic Medication Monitoring page for further details on antipsychotics and prolactin.
Red Flags
Urgent referral via eRS in the following cases:
- Visual field abnormalities
- Prolactin >5000mU/L – likely to represent a macroprolactinoma
- 9am cortisol < 100nmolL or symptoms suggestive of acute adrenal insufficiency (see separate adrenal insufficiency guidance).
Before referral
Take a full history and clinical examination of the following:
- Symptoms of hyperprolactinaemia – galactorrhoea, amenorrhoea, symptoms of hypogonadism/erectile dysfunction
- Chance of pregnancy/any breast feeding
- Headache history
- Visual field assessment – looking predominantly for peripheral visual field abnormalities
- Other signs and symptoms suggestive of concurrent pituitary hormone excess, particularly:
- Acromegaly - frontal bossing, increased shoe size, macroglossia and macrognathia
- Cushing’s disease - central adiposity, proximal myopathy, striae, easy bruising
- Possible medications causing a raised prolactin and their indication/long term need (may need discussion with other professions e.g. Psychiatry)
- Anti-psychotics e.g. phenothiazines, haloperidol, risperidone, fluoxetine, monoamine oxidase inhibitors
- Anti-emetics e.g. metoclopramide, domperidone
- Anti-convulsants
- Oestrogens including withdrawal of the contraceptive pill
- Opiates
- Verapamil
For likely medication induced symptomatic hyperprolactinaemia, stop the medication for 3 days OR switch to a mediation with lower dopamine antagonist potency e.g. aripiprazole (discuss with the patient’s team e.g. Psychiatry)
- Re-measure the prolactin after 3 days
- If the drug cannot be stopped, the raised prolactin doesn’t coincide with starting the medication OR the prolactin remains raised despite 3 days off medication, investigate and refer as below
Further investigations
- Pregnancy test – ensure this is done prior to referral.
- U&Es – renal failure causes enhanced production and decreased clearance of prolactin.
- Pituitary panel – 9am cortisol, LH, FSH, oestradiol/testosterone, IGF-1, TSH and free T4.
Services
Description of service:
• Adrenal Disorders
• Metabolic Bone Disorders
• Pituitary & Hypothalamic
• Thyroid / Parathyroid
Urgent advice pending review or for existing NBT Endocrine patients (if likely to change management within next 72 hours) the team can be contacted via:
Referral: Via e-referral system (eRS)
Description of service:
• Adrenal Disorders
• Metabolic Bone Disorders
• Pituitary & Hypothalamic
• Thyroid / Parathyroid
• Joint Thyroid/Eye Clinic
• Grave's Disease (Thyroid Eye Disease)
Please see the UHBW website for further information on specific clinics.
Urgent advice - ring switchboard and ask to be put through to the diabetes endocrine bleep holder.
Advice & Guidance is also available via eRS
Referral: Via e-referral system (eRS)
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.